Neuropore Initiates Phase 1 Clinical Trial in Healthy Volunteers with NPT520-34, a Therapeutic Candidate Aimed at Treating Parkinson?s Disease and Amyotrophic Lateral Sclerosis

SAN DIEGO–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ALS?src=hash" target="_blank"gt;#ALSlt;/agt;–Neuropore Therapies reenters the clinic with a second therapeutic candidate: NPT520-34